Chargement en cours...
Effectiveness of EGFR‐TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR‐RAD51 Fusion
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR‐TKIs) have become the first choice for patients with sensitive mutations and have significantly improved prognosis. EGFR exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarci...
Enregistré dans:
| Publié dans: | Oncologist |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons, Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693705/ https://ncbi.nlm.nih.gov/pubmed/31064887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0732 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|